The Valley Desk

Clinical trial reportCancer chemotherapy and pharmacologyPublished

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer chemotherapy and pharmacology
Published
Subject terms
Humans; Prostate-Specific Antigen; Glutamate Carboxypeptidase II; Antibodies, Bispecific; Antigens, Surface; Dose-Response Relationship, Drug; Aged; Aged, 80 and over; Middle Aged; Male; Prostatic Neoplasms, Castration-Resistant; CD3 Complex
PubMed ID
41493473
PubMed Central ID
PMC12774958
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal